Last reviewed · How we verify
Placebo to Salmeterol/fluticasone
Salmeterol is a long-acting beta2-adrenergic receptor agonist, while fluticasone is a corticosteroid that inhibits inflammatory processes.
Salmeterol is a long-acting beta2-adrenergic receptor agonist, while fluticasone is a corticosteroid that inhibits inflammatory processes. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | Placebo to Salmeterol/fluticasone |
|---|---|
| Sponsor | Novartis |
| Drug class | Long-acting beta2-adrenergic receptor agonist and corticosteroid |
| Target | Beta2-adrenergic receptor and glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Salmeterol works by binding to and activating the beta2-adrenergic receptor, leading to bronchodilation and improved lung function. Fluticasone, on the other hand, exerts its effects by inhibiting the release of pro-inflammatory cytokines and mediators, thereby reducing inflammation in the airways.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Headache
- Cough
- Oral thrush
- Bronchitis
- Sinusitis
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911) (PHASE3)
- Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Salmeterol/fluticasone CI brief — competitive landscape report
- Placebo to Salmeterol/fluticasone updates RSS · CI watch RSS
- Novartis portfolio CI